CONMED Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CONMED stock.
View analyst ratings for CONMED or view top-rated stocks.

Wall Street analysts have given CONMED a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CONMED wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

CONMED is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for CONMED.

CONMED will be holding an earnings conference call on Wednesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

CONMED Co. (NYSE:CNMD) issued its quarterly earnings data on Tuesday, January, 26th. The company reported $0.84 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.77 by $0.07. The company earned $252.80 million during the quarter, compared to analyst estimates of $262.94 million. CONMED had a trailing twelve-month return on equity of 9.48% and a net margin of 0.04%. The firm's revenue for the quarter was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.90 EPS.
View CONMED's earnings history.

CONMED's stock was trading at $78.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CNMD shares have increased by 67.4% and is now trading at $131.89.
View which stocks have been most impacted by COVID-19.

CONMED declared a quarterly dividend on Tuesday, February 23rd. Shareholders of record on Monday, March 15th will be paid a dividend of $0.20 per share on Monday, April 5th. This represents a $0.80 annualized dividend and a yield of 0.61%. The ex-dividend date of this dividend is Friday, March 12th.
View CONMED's dividend history.

CONMED pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.60%. The dividend payout ratio of CONMED is 30.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CONMED will have a dividend payout ratio of 26.23% next year. This indicates that CONMED will be able to sustain or increase its dividend.
View CONMED's dividend history.

CONMED issued an update on its FY21 earnings guidance on Wednesday, January, 27th. The company provided earnings per share guidance of $2.85-3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.02. The company issued revenue guidance of $975 million - $1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

6 analysts have issued 12 month target prices for CONMED's shares. Their forecasts range from $76.00 to $145.00. On average, they anticipate CONMED's stock price to reach $104.60 in the next year. This suggests that the stock has a possible downside of 20.7%.
View analysts' price targets for CONMED or view top-rated stocks among Wall Street analysts.

Some companies that are related to CONMED include Masimo (MASI), Getinge (GNGBY), LivaNova (LIVN), InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), ViewRay (VRAY), Stereotaxis (STXS), Cutera (CUTR), Zynex (ZYXI) and Edap Tms (EDAP).
View all of CNMD's competitors.

CONMED trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNMD."

CONMED's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Everence Capital Management Inc. (0.01%). Company insiders that own CONMED stock include Brian Concannon, Curt R Hartman, Daniel Jonas, Dirk Kuyper, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Mark E Tryniski, Peter K Shagory, Stanley W Peters III, Terence M Berge and Wilfredo Ruiz-Caban.
View institutional ownership trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold CONMED company stock in the last year include Brian Concannon, Curt R Hartman, Daniel Jonas, Johonna Marie Pelletier, Mark E Tryniski, Peter K Shagory, Stanley W Peters III, Terence M Berge, and Wilfredo Ruiz-Caban.
View insider buying and selling activity for CONMED or view top insider-selling stocks.

CNMD stock was bought by a variety of institutional investors in the last quarter, including Everence Capital Management Inc..
View insider buying and selling activity for CONMED or or view top insider-buying stocks.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNMD stock can currently be purchased for approximately $131.89.

CONMED has a market capitalization of $3.82 billion and generates $955.10 million in revenue each year. The company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis.

CONMED employs 3,400 workers across the globe.

The official website for CONMED is www.conmed.com.

CONMED is headquartered at 525 FRENCH ROAD, UTICA NY, 13502.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company can be reached via phone at 315 797 8375.